RLAY Relay Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • FDA clinical holds risk, with trials subject to suspension due to safety concerns or regulatory noncompliance impacting lead candidate development
• • Enrollment delays from competition with other therapies and limited eligible patients constrain trial timelines and regulatory approvals
• • Dependence on third-party CROs and diagnostic partners, which may fail to meet contractual or regulatory requirements, delaying trials and companion diagnostics approval
• • Competition for patient enrollment from other oncology trials, including Pfizer’s selective-CDK4 inhibitor in metastatic breast cancer combination study
• • High operational risk from novel mechanism drug candidates requiring extensive R&D and potential unknown adverse effects raising development costs and regulatory hurdles

Management Discussion & Analysis

• • Revenue $15.4M in 2025, up $5.3M YoY from $10.0M in 2024, primarily from Elevar Agreement milestones
• • Net loss $276.5M in 2025 vs $337.7M in 2024; operating expenses down to $318.1M from $382.5M; R&D $261.4M vs $319.1M, G&A $56.7M vs $76.6M
• • Best performing segment: License revenue from Elevar Agreement $15.4M in 2025; worst: Research & Development with $261.4M expense in 2025
• • Cash, cash equivalents, investments $554.5M as of Dec 31, 2025; raised $218.2M net in Sept 2024 offering; no share sales under $250M ATM facility; no disclosed dividends or buybacks
• • Management expects significant continued operating losses; cash runway into 2029; key risks include clinical trial progress, capital raising, regulatory approvals, and geopolitical/economic uncertainties

What are the latest RLAY SEC filings in 2026?

Relay Therapeutics, Inc. (RLAY) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did RLAY file its most recent 10-K annual report?

Relay Therapeutics, Inc. (RLAY) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view RLAY 10-Q quarterly reports?

Relay Therapeutics, Inc. (RLAY)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every RLAY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has RLAY filed recently?

Relay Therapeutics, Inc. (RLAY)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find RLAY insider trading activity (Form 4)?

SignalX aggregates every RLAY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does RLAY file with the SEC?

Relay Therapeutics, Inc. (RLAY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RLAY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Relay Therapeutics, Inc. (RLAY).

What is RLAY's SEC CIK number?

Relay Therapeutics, Inc. (RLAY)'s SEC CIK (Central Index Key) number is 1812364. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1812364 to look up all RLAY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find RLAY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Relay Therapeutics, Inc. (RLAY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.